Complement C8 deficient serum human

Description

• Application: Complement C8 is one of the end terminals of the complement system contained in the membrane attack complex (MAC). A deficiency of C8 may result in an increased susceptibility to Neisseria meningitidis. The most common mutation resulting in a C8 deficiency is a C to T transition in exon 9 of the C8 beta gene. Recent research however, has also discovered that two separate heterogeneous mutations may result in C8 deficiency in patients displaying recurrent meningococcal meningitis. These mutations are a duplication mutation on exon 7 and a mutation on exon 3.
• Biochem/physiol Actions: Serum naturally deficient in C8 may actually contain some C8, though in greatly reduced quantity. Terminal complement complex is present at trace levels in such sera.[1]
• Physical form: Supplied as a solution in PBS, pH 7.3
• Analysis Note: C8 is depleted by immunoadsorption as judged by a highly sensitive hemolytic assay.
• Disclaimer: RESEARCH USE ONLY. This product is regulated in France when intended to be used for scientific purposes, including for import and export activities (Article L 1211-1 paragraph 2 of the Public Health Code). The purchaser (i.e. enduser) is required to obtain an import authorization from the France Ministry of Research referred in the Article L1245-5-1 II. of Public Health Code. By ordering this product, you are confirming that you have obtained the proper import authorization.